Evotec SE (EVO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EVO Revenue Growth
Revenue Breakdown (FY 2025)
EVO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
EVO Revenue Analysis (2014–2025)
As of May 8, 2026, Evotec SE (EVO) generated trailing twelve-month (TTM) revenue of $786.0 million, reflecting strong growth of +13.4% year-over-year. The most recent quarter (Q4 2025) recorded $250.9 million in revenue, up 53.1% sequentially.
Looking at the longer-term picture, EVO's 5-year compound annual growth rate (CAGR) stands at +8.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $797.0 million in 2024.
Revenue diversification analysis shows EVO's business is primarily driven by Other Fees (100%). With over half of revenue concentrated in Other Fees, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IQV (+7.3% YoY), CRL (+0.1% YoY), and MEDP (+24.2% YoY), EVO has underperformed the peer group in terms of revenue growth. Compare EVO vs IQV →
EVO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVOCurrent | $786M | +13.4% | +8.6% | -17.9% | |
 IQV | $16.3B | +7.3% | +7.5% | 14.0% | |
 CRL | $4.0B | +0.1% | +6.5% | 12.6% | |
 MEDP | $2.5B | +24.2% | +22.3% | 21.1% | |
 LSCC | $523M | +17.4% | +5.1% | 2.9% | |
 RXRX | $75M | +11.0% | +85.4% | -867.9% |
EVO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $757.3M | -5.0% | $62.7M | 8.3% | $-135,312,161 | -17.9% |
| 2024 | $797.0M | +2.0% | $114.9M | 14.4% | $-142,522,000 | -17.9% |
| 2023 | $781.4M | +4.0% | $175.1M | 22.4% | $-47,507,000 | -6.1% |
| 2022 | $751.4M | +21.6% | $174.1M | 23.2% | $20.9M | 2.8% |
| 2021 | $618.0M | +23.4% | $151.5M | 24.5% | $41.0M | 6.6% |
| 2020 | $500.9M | +12.2% | $125.7M | 25.1% | $48.6M | 9.7% |
| 2019 | $446.4M | +18.9% | $132.9M | 29.8% | $62.6M | 14.0% |
| 2018 | $375.4M | +45.7% | $112.0M | 29.8% | $77.5M | 20.6% |
| 2017 | $257.6M | +56.6% | $82.6M | 32.0% | $37.5M | 14.6% |
| 2016 | $164.5M | +28.8% | $58.6M | 35.6% | $31.3M | 19.1% |
See EVO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVO — Frequently Asked Questions
Quick answers to the most common questions about buying EVO stock.
Is EVO's revenue growth accelerating or slowing?
EVO maintains +13.4% revenue growth, in line with its 5-year CAGR of +8.6%. TTM revenue stands at $786M. Growth rate remains consistent with historical average.
What is EVO's long-term revenue growth rate?
Evotec SE's 5-year revenue CAGR of +8.6% reflects the sustained expansion pattern. Current YoY growth of +13.4% is near this long-term average.
How is EVO's revenue distributed by segment?
EVO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.